Sanofi to invest $324m in entity with Orano Med for radioligand therapy
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the.
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.
French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply.